MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
01. Mai 2024 07:45 ET
|
mdxhealth
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million, previously...
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
12. März 2024 16:00 ET
|
mdxhealth
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering IRVINE, CA, and HERSTAL, BELGIUM – March 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the “Company” or...
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
06. März 2024 16:00 ET
|
mdxhealth
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42%2023 gross margin expanded by 10.7 percentage points...
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
21. Februar 2024 17:00 ET
|
mdxhealth
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6 Company to Host Conference Call with Live Q&A, March 6, 2024 at 4:30pm ET / 22:30 CET ...
Mdxhealth Announces Resignation of Board Member
16. Februar 2024 08:45 ET
|
mdxhealth
Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a commercial-stage...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance
08. Januar 2024 16:00 ET
|
mdxhealth
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue Guidance IRVINE, CA, and HERSTAL, BELGIUM – January 8, 2024 (GlobeNewswire) – MDxHealth...
MDxHealth annonce la réalisation de sa transition vers une cotation unique sur le Nasdaq
18. Dezember 2023 01:00 ET
|
mdxhealth
COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE18 DECEMBRE 2023, 01:00 ET / 07:00 CET MDxHealth annonce la réalisation de sa transition vers une cotation unique sur le Nasdaq IRVINE,...
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
18. Dezember 2023 01:00 ET
|
mdxhealth
NEWS RELEASE – REGULATED INFORMATIONDECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL,...
MDxHealth annonce la réalisation de l'échange obligatoire d'ADS et le début de la période de transition vers une cotation unique sur le Nasdaq
27. November 2023 01:00 ET
|
mdxhealth
COMMUNIQUÉ DE PRESSE - INFORMATION RÉGLEMENTÉE27 NOVEMBRE 2023, 1:00 EDT / 7:00 CET MDxHealth annonce la réalisation de l'échange obligatoire d'ADS et le début de la période de transition vers une...
MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq
27. November 2023 01:00 ET
|
mdxhealth
NEWS RELEASE – REGULATED INFORMATIONNOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on...